p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours.
The MDM2 gene is amplified and/or overexpressed in about 10% of glioblastomas and constitutes one of a number of ways the p53 pathway is disrupted in these tumours. MDM2 encodes a nuclear phosphoprotein that regulates several cell proteins by binding and/or ubiquitinating them, with p53 being a well-established partner. MDM2 has two promoters, P1 and P2 that give rise to transcripts with distinct 5' untranslated regions. Transcription from P2 is believed to be controlled by p53 and a single-nucleotide polymorphism (SNP309, T>G) in P2 is reported to be associated with increased risk for, and early development of, malignancies. The use of P1 and P2 has not been investigated in gliomas. We used RT-PCR to study P1- and P2-MDM2 transcript expression in astrocytic tumours, xenografts and cell lines with known MDM2, TP53 and p14(ARF) gene status. Both promoters were used in all genetic backgrounds including the use of the P2 promoter in TP53 null cells, indicating a p53-independent induction of transcription. Transcripts from the P1 promoter formed a greater proportion of the total MDM2 transcripts in tumours with MDM2 amplification, despite these tumours having two wild-type TP53 alleles. Examination of SNP309 in glioblastoma patients showed a borderline association with survival but no apparent correlation with age at diagnosis nor with TP53 and p14(ARF) status of their tumours. Our findings also indicate that elevated MDM2 mRNA levels in tumours with MDM2 amplification are preferentially driven by the P1 promoter and that the P2 promoter is not only regulated by p53 but also by other transcription factor(s).
Dimitriadi
M
M
Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Box 231, Cambridge CB2 0QQ, UK. mdimitriadi@cantab.net
Poulogiannis
G
G
Liu
L
L
Bäcklund
L M
LM
Pearson
D M
DM
Ichimura
K
K
Collins
V P
VP
D000328:Adult; D001932:Brain Neoplasms / Q000235:genetics*; D005838:Genotype; D005909:Glioblastoma / Q000235:genetics*; D006801:Humans; D011401:Promoter Regions, Genetic; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016159:Tumor Suppressor Protein p53 / Q000502:physiology*
D012333:RNA, Messenger; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2
J Neuropathol Exp Neurol. 1999 Nov;58(11):1170-83
10560660
Cancer Res. 1993 Jun 15;53(12):2736-9
8504413
J Biol Chem. 2004 Jul 9;279(28):29841-8
15090541
Int Rev Exp Pathol. 1983;24:135-202
6601641
Nature. 1997 May 15;387(6630):299-303
9153396
Genes Dev. 2005 Sep 15;19(18):2122-37
16131611
Oral Oncol. 2001 Dec;37(8):620-31
11590071
Neurol Med Chir (Tokyo). 2007 May;47(5):203-8; discussion 208-9
17527046
Clin Cancer Res. 2003 Sep 15;9(11):4151-8
14519639
Curr Cancer Drug Targets. 2005 Feb;5(1):9-20
15720185
Eur J Cancer. 1999 Jul;35(7):1083-8
10533452
Mol Cell Biol. 1999 Jan;19(1):864-72
9858609
Oncol Rep. 2002 May-Jun;9(3):557-63
11956627
Mol Cancer Res. 2003 Dec;1(14):1017-26
14707285
J Neurooncol. 2007 Dec;85(3):241-4
17568997
Oncogene. 2002 Mar 27;21(13):1955-62
11960368
J Mol Med (Berl). 2005 Nov;83(11):917-26
16133418
Leukemia. 2005 Nov;19(11):1996-8
16167062
Cancer Res. 1997 Aug 15;57(16):3562-8
9270029
Cell. 2004 Nov 24;119(5):591-602
15550242
Int J Cancer. 2007 Feb 1;120(3):563-5
17096342
Oncogene. 2000 Feb 10;19(6):831-5
10698502
Clin Cancer Res. 2007 Jun 1;13(11):3215-20
17545525
Anticancer Res. 2006 Nov-Dec;26(6C):4975-7
17214373
Acta Neuropathol. 2007 Aug;114(2):97-109
17618441
Nucleic Acids Res. 1998 Aug 1;26(15):3453-9
9671804
Cell. 2000 Oct 13;103(2):321-30
11057904
Cell. 1992 Jun 26;69(7):1237-45
1535557
Oncogene. 2006 Jul 13;25(30):4183-93
16501602
Mol Cell Biol. 2000 Mar;20(6):2023-30
10688649
Oncogene. 2001 May 31;20(25):3193-205
11423969
Cancer Cell. 2007 Oct;12(4):303-12
17936556
Genes Chromosomes Cancer. 2005 Jun;43(2):181-93
15770670
Nucleic Acids Res. 1995 Jul 25;23(14):2584-92
7651818
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7
9653180
J Biol Chem. 2003 Jul 11;278(28):25716-21
12730202
Oncogene. 2007 Feb 26;26(9):1317-23
17322917
J Biol Chem. 2005 Apr 29;280(17):16651-8
15723837
Int J Cancer. 2000 May 20;89(3):265-70
10861503
Oncogene. 1996 Sep 5;13(5):1065-72
8806696
Cancer Res. 1998 Nov 15;58(22):5061-5
9823311
Brain Res. 2008 Mar 10;1198:16-20
18262501
Mol Cell Biol. 2004 Apr;24(8):3536-51
15060172
Cancer Res. 2001 Feb 15;61(4):1598-603
11245471
Cancer Res. 2005 Oct 15;65(20):9582-7
16230424
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14517-22
10588737
Cancer Lett. 2006 Aug 28;240(2):195-7
16239061
Leuk Lymphoma. 1995 Mar;17(1-2):13-8
7773150
Cancer Lett. 2001 Mar 26;164(2):177-88
11179833
Oncogene. 2008 Mar 27;27(14):2097-108
17934521
Genes Dev. 1994 Aug 1;8(15):1739-49
7958853
Am J Pathol. 2000 Aug;157(2):587-96
10934161
Cancer Res. 2000 Jan 15;60(2):417-24
10667596
Cancer Res. 2003 May 15;63(10):2616-23
12750288
Nature. 1997 May 15;387(6630):296-9
9153395
Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1559-61
16896050
Oncogene. 1998 Apr 30;16(17):2249-57
9619834
Clin Cancer Res. 2005 Feb 1;11(3):1119-28
15709179